Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   

Alzheimer’s Disease

behavioural deterioration1 - brain plaques1 - slowness of movement1 - brain cell damage2 - neuritic plaque1 - anoea1 - high oestrogen levels1 - cognitive health3 - vessel disease1 - risk of death1 - physical exercise1 - type of dementia4 - pomegranate1 - islet amyloid polypeptide1 - alzheimer's disease prevention1 - disorders of blood vessels1 - brewer1 - amyloid beta 421 - emotional distress1 - deep-brain stimulation3 - causes of the dementia1 - structural imaging1 - development of alzheimer's1 - pdd3 - fischer1 - genomic dna1 - alzheimer’s disease1 - senile atrophy and aphasia1 - sleep disturbances1 - confabulatory euphoria1 -